Targeted Tumor Destruction: High-Throughput Assessment
Antibody-drug conjugates (ADCs) are designed to eliminate cancer cells, by judiciously combining the potency of chemotherapeutic agents with the specificity of monoclonal antibody immunotherapy. The development of efficient in vitro methods to measure the toxic effects of ADCs on cancer cells, is fundamental for accelerating drug development pipelines.
In this webinar, we demonstrate the use of high-throughput cytometry in evaluating the efficacy of ADCs which target the HER2 protein on cancer cells. The effectiveness of these ADCs was explored using both traditional 2D monolayer cultures, and intricate 3D tumor spheroids which better mimic the tumor environment in the body.
Complete the Form to Access the Webinar
Sartorius
Kirsty McBain is a Scientist in the BioAnalytics Group of Sartorius, where she is involved in the research and development of novel applications.
Kirsty’s efforts are focused on the iQue® Platform where she has supported a number of the immuno-oncology campaigns that are used to exemplify how Sartorius technology can be applied to the drug discovery process. Kirsty obtained a master’s degree in Biochemistry at the University of Bristol before joining Sartorius in 2019.
Please select your country so we can show you products that are available for you.
The content of our website is always available in English and partly in other languages. Choose your preferred language and we will show you the content in that language, if available.
Shop Sartorius Products Now